Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 104, Issue 1, Pages 6-17Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-016-2039-6
Keywords
Adoptive T cell therapy; Chimeric antigen receptor; CD19; Immunotherapy; T cell engineering
Categories
Funding
- NCI NIH HHS [K12 CA090625, P30 CA008748] Funding Source: Medline
Ask authors/readers for more resources
Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy. We review here the T cell biology and cell engineering research that led to the development of second generation CARs, the selection of CD19 as a CAR target, and the preclinical studies in animal models that laid the foundation for clinical trials targeting CD19+ malignancies. We further summarize the status of CD19 CAR clinical therapy for non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia, including their efficacy, toxicities (cytokine release syndrome, neurotoxicity and B cell aplasia) and current management in humans. We conclude with an overview of recent pre-clinical advances in CAR design that argues favorably for the advancement of CAR therapy to tackle other hematological malignancies as well as solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available